Integra LifeSciences (NASDAQ:IART) Rating Increased to Buy at Argus

Argus upgraded shares of Integra LifeSciences (NASDAQ:IART) from a hold rating to a buy rating in a report issued on Monday morning, Marketbeat Ratings reports.

Separately, Morgan Stanley began coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price for the company. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Trading Up 1.4 %

Shares of IART stock opened at $21.99 on Monday. The company has a 50 day moving average price of $23.74 and a 200 day moving average price of $22.24. The stock has a market capitalization of $1.70 billion, a P/E ratio of -244.31, a price-to-earnings-growth ratio of 0.73 and a beta of 1.23. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $35.45.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter last year, the business posted $0.89 EPS. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. Equities research analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

A number of institutional investors have recently modified their holdings of IART. Sachem Head Capital Management LP acquired a new stake in shares of Integra LifeSciences in the 3rd quarter worth approximately $44,153,000. Paradigm Capital Management Inc. NY lifted its stake in shares of Integra LifeSciences by 170.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock worth $32,457,000 after purchasing an additional 901,600 shares during the period. Capital Research Global Investors boosted its holdings in shares of Integra LifeSciences by 7.4% during the fourth quarter. Capital Research Global Investors now owns 1,400,559 shares of the life sciences company’s stock worth $31,765,000 after purchasing an additional 95,944 shares during the last quarter. Lord Abbett & CO. LLC increased its stake in Integra LifeSciences by 86.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company’s stock valued at $30,210,000 after purchasing an additional 618,773 shares during the last quarter. Finally, Soleus Capital Management L.P. purchased a new position in Integra LifeSciences during the fourth quarter worth about $28,940,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.